Chronic kidney disease (CKD) is the leading complication in type 2 diabetes (T2D) and current therapies that limit CKD progression and the development of cardiovascular disease (CVD) include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and sodium–glucose co-transporter 2 (SGLT2) inhibitors. Despite the introduction of these therapeutics, an important residual risk of CKD progression and cardiovascular death remains in patients with T2D. Mineralocorticoid receptor antagonists (MRAs) are a promising therapeutic option in diabetic kidney disease (DKD) owing to the reported effects of mineralocorticoid receptor activation in inflammatory cells, podocytes, fibroblasts, mesangial cells and vascular cells. In preclinical studies, MRAs consistently reduce albuminuria, CKD progression, and activation of fibrotic and inflammatory pathways. DKD clinical studies have similarly demonstrated that steroidal MRAs lead to albuminuria reduction compared with placebo, although hyperkalaemia is a major secondary effect. Non-steroidal MRAs carry a lower risk of hyperkalaemia than steroidal MRAs, and the large FIDELIO-DKD clinical trial showed that the non-steroidal MRA finerenone also slowed CKD progression and reduced the risk of adverse cardiovascular outcomes compared with placebo in patients with T2D. Encouragingly, other non-steroidal MRAs have anti-albuminuric properties in DKD. Whether or not combining MRAs with other renoprotective drugs such as SGLT2 inhibitors might provide additive protective effects warrants further investigation.
Current therapeutic options to slow the progression of chronic kidney disease (CKD) in type 2 diabetes (T2D) and reduce its cardiovascular consequences mainly include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and sodium–glucose co-transporter 2 inhibitors. However, the residual risk of CKD progression and cardiovascular death remains high.
Mineralocorticoid receptor activation in non-epithelial cells leads to the activation of inflammatory and fibrotic pathways in the kidney, and has deleterious effects in podocytes and mesangial cells.
Pharmacological inhibition of the mineralocorticoid receptor reduces albuminuria, kidney fibrosis, glomerular lesions and inflammation in preclinical models of CKD in T2D; beneficial cardiovascular effects have also been observed.
Clinical studies show that steroidal mineralocorticoid receptor antagonists (MRAs) have an anti-albuminuric effect in diabetic kidney disease, but the risk of hyperkalaemia associated with the use of these drugs has limited their use and evaluation for hard kidney and cardiovascular outcomes.
Promising novel non-steroidal MRAs with a better therapeutic index than steroidal MRAs have been developed — in the FIDELIO-DKD trial, finerenone reduced CKD progression and improved cardiovascular outcomes compared with placebo when added to an optimized regimen of renin–angiotensin–aldosterone system inhibitors and the incidence of hyperkalaemia was very low. Other non-steroidal MRAs reduced albuminuria in phase II and phase III clinical trials.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Jager, K. J. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 96, 1048–1050 (2019).
Doshi, S. M. & Friedman, A. N. Diagnosis and management of type 2 diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 12, 1366–1373 (2017).
Di Lullo, L. et al. Chronic kidney disease and cardiovascular complications. Heart Fail. Rev. 20, 259–272 (2015).
Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456–1462 (1993).
Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).
Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).
Tuttle, K. R. et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin. J. Am. Soc. Nephrol. 2, 631–636 (2007).
Mann, J. F. et al. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527–535 (2010).
Sharma, K. et al. Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol. 22, 1144–1151 (2011).
Packham, D. K. et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 23, 123–130 (2012).
Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204–2213 (2012).
Fried, L. F. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369, 1892–1903 (2013).
de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492–2503 (2013).
Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).
McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).
Anker, S. D. et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced Trial. Circulation 143, 337–349 (2021).
Hannedouche, T. et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309, 833–837 (1994).
Bakris, G. L., Copley, J. B., Vicknair, N., Sadler, R. & Leurgans, S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 50, 1641–1650 (1996).
Bakris, G. L., Mangrum, A., Copley, J. B., Vicknair, N. & Sadler, R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 29, 744–750 (1997).
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).
Jaisser, F. & Farman, N. Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol. Rev. 68, 49–75 (2016).
Barrera-Chimal, J., Girerd, S. & Jaisser, F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 96, 302–319 (2019).
Kolkhof, P. & Barfacker, L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J. Endocrinol. 234, T125–T140 (2017).
Pearce, D. et al. Collecting duct principal cell transport processes and their regulation. Clin. J. Am. Soc. Nephrol. 10, 135–146 (2015).
Rossier, B. C., Baker, M. E. & Studer, R. A. Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol. Rev. 95, 297–340 (2015).
Briet, M. & Schiffrin, E. L. Aldosterone: effects on the kidney and cardiovascular system. Nat. Rev. Nephrol. 6, 261–273 (2010).
Shibata, S. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron. J. Endocrinol. 234, T35–T47 (2017).
Mihailidou, A. S., Tzakos, A. G. & Ashton, A. W. Non-genomic effects of aldosterone. Vitam. Horm. 109, 133–149 (2019).
Funder, J. W. The nongenomic actions of aldosterone. Endocr. Rev. 26, 313–321 (2005).
He, B. J. et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat. Med. 17, 1610–1618 (2011).
Agarwal, R. et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 42, 152–161 (2021).
Brilla, C. G., Pick, R., Tan, L. B., Janicki, J. S. & Weber, K. T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. 67, 1355–1364 (1990).
Brilla, C. G., Matsubara, L. S. & Weber, K. T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell Cardiol. 25, 563–575 (1993).
Rocha, R. et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283, H1802–H1810 (2002).
Tostes, R. C., Touyz, R. M., He, G., Chen, X. & Schiffrin, E. L. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin. Sci. 103 (Suppl. 48), 25S–30S (2002).
Blasi, E. R. et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63, 1791–1800 (2003).
Ferreira, N. S., Tostes, R. C., Paradis, P. & Schiffrin, E. L. Aldosterone, inflammation, immune system, and hypertension. Am. J. Hypertens. 34, 15–27 (2021).
Ko, E. A. et al. Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 292, H1789–H1795 (2007).
Thang, L. V. et al. Macrophage depletion lowers blood pressure and restores sympathetic nerve α2-adrenergic receptor function in mesenteric arteries of DOCA-salt hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 309, H1186–H1197 (2015).
Ferreira, N. S. et al. NLRP3 inflammasome and mineralocorticoid receptors are associated with vascular dysfunction in type 2 diabetes mellitus. Cells 8, 1595 (2019).
Schunk, S. J. et al. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur. Heart J. 42, 1742–1756 (2021).
Syed, M. et al. MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction. Am. J. Physiol. Endocrinol. Metab. 315, E1154–E1167 (2018).
Buonafine, M. et al. Neutrophil gelatinase-associated lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. J. Mol. Cell Cardiol. 115, 32–38 (2018).
Araos, P. et al. Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation. J. Hypertens. 37, 1482–1492 (2019).
Herrada, A. A. et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J. Immunol. 184, 191–202 (2010).
Amador, C. A. et al. Spironolactone decreases DOCA–salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 63, 797–803 (2014).
Krebs, C. F. et al. Deficiency of the interleukin 17/23 axis accelerates renal injury in mice with deoxycorticosterone acetate+angiotensin II-induced hypertension. Hypertension 63, 565–571 (2014).
Shao, P. P. et al. Eplerenone reverses cardiac fibrosis via the suppression of Tregs by inhibition of Kv1.3 channel. Front. Physiol. 9, 899 (2018).
Usher, M. G. et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 120, 3350–3364 (2010).
Fraccarollo, D. et al. Macrophage mineralocorticoid receptor is a pleiotropic modulator of myocardial infarct healing. Hypertension 73, 102–111 (2019).
Li, C. et al. Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLoS ONE 9, e110950 (2014).
Montes-Cobos, E. et al. Deletion of the mineralocorticoid receptor in myeloid cells attenuates central nervous system autoimmunity. Front. Immunol. 8, 1319 (2017).
Frieler, R. A. et al. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 42, 179–185 (2011).
Barrera-Chimal, J. et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 93, 1344–1355 (2018).
Huang, L. L. et al. Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J. Am. Soc. Nephrol. 25, 2231–2240 (2014).
Shen, J. Z. et al. Cardiac tissue injury and remodeling is dependent upon MR regulation of activation pathways in cardiac tissue macrophages. Endocrinology 157, 3213–3223 (2016).
Sun, J. Y. et al. Mineralocorticoid receptor deficiency in macrophages inhibits neointimal hyperplasia and suppresses macrophage inflammation through SGK1-AP1/NF-κB pathways. Arterioscler. Thromb. Vasc. Biol. 36, 874–885 (2016).
Ong, G. S. Y. et al. Novel mineralocorticoid receptor mechanisms regulate cardiac tissue inflammation in male mice. J. Endocrinol. 246, 123–134 (2020).
Rickard, A. J. et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54, 537–543 (2009).
Armanini, D., Endres, S., Kuhnle, U. & Weber, P. C. Parallel determination of mineralocorticoid and glucocorticoid receptors in T- and B-lymphocytes of human spleen. Acta Endocrinol. 118, 479–482 (1988).
Sun, X. N. et al. T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma. Circ. Res. 120, 1584–1597 (2017).
Li, C. et al. Mineralocorticoid receptor deficiency in T cells attenuates pressure overload-induced cardiac hypertrophy and dysfunction through modulating T-cell activation. Hypertension 70, 137–147 (2017).
Barrera-Chimal, J. et al. Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation. Nephrol. Dial. Transpl. 34, 794–801 (2018).
Ahmed, A. S. & Antonsen, E. L. Immune and vascular dysfunction in diabetic wound healing. J. Wound Care 25, S35–S46 (2016).
Dangwal, S. et al. Impairment of wound healing in patients with type 2 diabetes mellitus influences circulating MicroRNA patterns via inflammatory cytokines. Arterioscler. Thromb. Vasc. Biol. 35, 1480–1488 (2015).
Nguyen, V. T. et al. Cutaneous wound healing in diabetic mice is improved by topical mineralocorticoid receptor blockade. J. Invest. Dermatol. 140, 223–234.e7 (2020).
Miric, G. et al. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. Pharmacol. 133, 687–694 (2001).
Fujisawa, G. et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. 66, 1493–1502 (2004).
Yuan, J., Jia, R. & Bao, Y. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J. Renin Angiotensin Aldosterone Syst. 8, 118–126 (2007).
Guo, C. et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147, 5363–5373 (2006).
Han, K. H. et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int. 70, 111–120 (2006).
Han, S. Y. et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J. Am. Soc. Nephrol. 17, 1362–1372 (2006).
Taira, M. et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur. J. Pharmacol. 589, 264–271 (2008).
Toyonaga, J. et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol. Dial. Transpl. 26, 2475–2484 (2011).
Li, Z. et al. Spironolactone inhibits podocyte motility via decreasing integrin beta1 and increasing integrin beta3 in podocytes under high-glucose conditions. Mol. Med. Rep. 12, 6849–6854 (2015).
Dong, D. et al. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. Int. Urol. Nephrol. 51, 755–764 (2019).
Zhu, D. et al. Spironolactone inhibits apoptosis in rat mesangial cells under hyperglycaemic conditions via the Wnt signalling pathway. Mol. Cell Biochem. 380, 185–193 (2013).
Yoshida, S. et al. Local mineralocorticoid receptor activation and the role of Rac1 in obesity-related diabetic kidney disease. Nephron Exp. Nephrol. 126, 16–24 (2014).
Koszegi, S. et al. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition. J. Physiol. 597, 193–209 (2019).
Banki, N. F. et al. Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats. PLoS ONE 7, e39938 (2012).
Pessoa, B. S., Peixoto, E. B., Papadimitriou, A., Lopes de Faria, J. M. & Lopes de Faria, J. B. Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat. J. Renin Angiotensin Aldosterone Syst. 13, 56–66 (2012).
Lian, M. et al. Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. Nephrol. Dial. Transpl. 27, 906–912 (2012).
Kang, Y. S. et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol. Dial. Transpl. 24, 73–84 (2009).
Zhou, G., Johansson, U., Peng, X. R., Bamberg, K. & Huang, Y. An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. Am. J. Transl. Res. 8, 1339–1354 (2016).
Kolkhof, P. et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol. 64, 69–78 (2014).
Kolkhof, P., Nowack, C. & Eitner, F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr. Opin. Nephrol. Hypertens. 24, 417–424 (2015).
Grune, J. et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone’s antifibrotic activity. Hypertension 71, 599–608 (2018).
Bhuiyan, A. S. et al. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. Hypertens. Res. 42, 892–902 (2019).
Bamberg, K. et al. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS ONE 13, e0193380 (2018).
Lachaux, M. et al. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. Diabetes Obes. Metab. 20, 2399–2407 (2018).
Liu, W. et al. Spironolactone protects against diabetic cardiomyopathy in streptozotocin-induced diabetic rats. J. Diabetes Res. 2018, 9232065 (2018).
Mayyas, F., Alzoubi, K. H. & Bonyan, R. The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin-induced diabetes. Cardiovasc Ther. 2018, 9232065 (2018).
Bonnard, B. et al. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. J. Mol. Cell Cardiol. 121, 124–133 (2018).
Silva, M. A. et al. Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. Front. Physiol. 6, 269 (2015).
Lefranc, C. et al. MR (Mineralocorticoid Receptor) induces adipose tissue senescence and mitochondrial dysfunction leading to vascular dysfunction in obesity. Hypertension 73, 458–468 (2019).
Nguyen Dinh Cat, A. et al. Vascular dysfunction in obese diabetic db/db mice involves the interplay between aldosterone/mineralocorticoid receptor and Rho kinase signaling. Sci. Rep. 8, 2952 (2018).
Brown, S. M., Meuth, A. I., Davis, J. W., Rector, R. S. & Bender, S. B. Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction: a unique vascular transcriptomic signature. Pharmacol. Res. 134, 100–108 (2018).
DuPont, J. J. & Jaffe, I. Z. 30 years of the mineralocorticoid receptor: the role of the mineralocorticoid receptor in the vasculature. J. Endocrinol. 234, T67–T82 (2017).
Barrera-Chimal, J. & Jaisser, F. Vascular mineralocorticoid receptor activation and disease. Exp. Eye Res. 188, 107796 (2019).
Aroor, A. R. et al. Diet-induced obesity promotes kidney endothelial stiffening and fibrosis dependent on the endothelial mineralocorticoid receptor. Hypertension 73, 849–858 (2019).
Schjoedt, K. J. et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70, 536–542 (2006).
Schjoedt, K. J. et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 68, 2829–2836 (2005).
Sato, A., Hayashi, K. & Saruta, T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am. J. Hypertens. 18, 44–49 (2005).
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. & Toto, R. D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641–2650 (2009).
Mavrakanas, T. A., Gariani, K. & Martin, P. Y. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Eur. J. Intern. Med. 25, 173–176 (2014).
El Mokadem, M., Abd El Hady, Y. & Aziz, A. A prospective single-blind randomized trial of ramipril, eplerenone and their combination in type 2 diabetic nephropathy. Cardiorenal Med. 10, 392–401 (2020).
Brandt-Jacobsen, N. H. et al. Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: data from the MIRAD trial. Diabetes Metab. 47, 101190 (2020).
Cooper, L. B. et al. Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. J. Am. Heart Assoc. 6, e006540 (2017).
Bakris, G. L. et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314, 884–894 (2015).
Katayama, S. et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J. Diabetes Complications 31, 758–765 (2017).
Wada, T. et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin. Exp. Nephrol. 25, 120–130 (2021).
Ito, S., Shikata, K., Nangaku, M., Okuda, Y. & Sawanobori, T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clin. J. Am. Soc. Nephrol. 14, 1161–1172 (2019).
Ito, S. et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin. J. Am. Soc. Nephrol. 15, 1715–1727 (2020).
Lindhardt, M. et al. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. Nephrol. Dial. Transpl. 33, 296–303 (2018).
Mulder, S. et al. Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes. Transl. Res. 222, 17–27 (2020).
Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709–717 (1999).
Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309–1321 (2003).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01848639 (2020).
Filippatos, G. et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur. Heart J. 37, 2105–2114 (2016).
Filippatos, G. et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation 143, 540–552 (2021).
Filippatos, G. et al. Finerenone reduces onset of atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J. Am. Coll. Cardiol. 78, 142–152 (2021).
Ruilope, L. M. et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am. J. Nephrol. 50, 345–356 (2019).
Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2110956 (2021).
Lazich, I. & Bakris, G. L. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin. Nephrol. 34, 333–339 (2014).
Khosla, N., Kalaitzidis, R. & Bakris, G. L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am. J. Nephrol. 30, 418–424 (2009).
Yang, C. T., Kor, C. T. & Hsieh, Y. P. Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease. J. Clin. Med. 7, 459 (2018).
Quach, K. et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis. Am. J. Kidney Dis. 68, 591–598 (2016).
Charytan, D. M. et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int. 95, 973–982 (2019).
Rossignol, P., Frimat, L. & Zannad, F. The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward. Kidney Int. 95, 747–749 (2019).
Hill, N. R. et al. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial — a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials 15, 160 (2014).
Bakris, G., Yang, Y. F. & Pitt, B. Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial. Hypertension 76, 144–149 (2020).
Weir, M. R. et al. Effect of patiromer on hyperkalemia recurrence in older chronic kidney disease patients taking RAAS inhibitors. Am. J. Med. 131, 555–564 e553 (2018).
Rossignol, P., Fay, R., Girerd, N. & Zannad, F. Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post-discharge. ESC Heart Fail. 7, 1257–1263 (2020).
Rakugi, H., Ito, S., Itoh, H., Okuda, Y. & Yamakawa, S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens. Res. 42, 1932–1941 (2019).
Zhang, Y. et al. Effects and safety of a novel oral potassium-lowering drug-sodium zirconium cyclosilicate for the treatment of hyperkalemia: a systematic review and meta-analysis. Cardiovasc. Drugs Ther. 35, 1057–1066 (2021).
Ali, W. & Bakris, G. Evolution of patiromer use: a review. Curr. Cardiol. Rep. 22, 94 (2020).
Clase, C. M. et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 97, 42–61 (2020).
Agarwal, R. et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 394, 1540–1550 (2019).
Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
Mahaffey, K. W. et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 140, 739–750 (2019).
Mosenzon, O. et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 7, 606–617 (2019).
Yamada, T. et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc. Diabetol. 20, 14 (2021).
Mittal, N., Sehray, V., Mittal, R. & Singh, S. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: summary evidence from clinical and real-world data. Eur. J. Pharmacol. 907, 174320 (2021).
Wu, H. et al. Comparative analysis and refinement of human PSC-derived kidney organoid differentiation with single-cell transcriptomics. Cell Stem Cell 23, 869–881.e8 (2018).
Wu, H., Kirita, Y., Donnelly, E. L. & Humphreys, B. D. Advantages of single-nucleus over single-cell RNA sequencing of adult kidney: rare cell types and novel cell states revealed in fibrosis. J. Am. Soc. Nephrol. 30, 23–32 (2019).
Wilson, P. C. et al. The single-cell transcriptomic landscape of early human diabetic nephropathy. Proc. Natl Acad. Sci. USA 116, 19619–19625 (2019).
Bakris, G. et al. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m(2): Subgroup Analysis of the Randomized CREDENCE Trial. Clin. J. Am. Soc. Nephrol. 15, 1705–1714 (2020).
Sternlicht, H. & Bakris, G. L. Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis. Curr. Hypertens. Rep. 21, 12 (2019).
Higashikawa, T. et al. Effects of tofogliflozin on cardiac function in elderly patients with diabetes mellitus. J. Clin. Med. Res. 12, 165–171 (2020).
Solini, A. et al. The effects of dapagliflozin on systemic and renal vascular function display an epigenetic signature. J. Clin. Endocrinol. Metab. 104, 4253–4263 (2019).
Schork, A. et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc. Diabetol. 18, 46 (2019).
Shin, S. J. et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS ONE 11, e0165703 (2016).
Kolkhof, P. et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52, 642–652 (2021).
Shen, L. et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail. 9, 254–264 (2021).
Ferreira, J. P. et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J. Am. Coll. Cardiol. 77, 1397–1407 (2021).
Greene, S. J. & Khan, M. S. Quadruple medical therapy for heart failure: medications working together to provide the best care. J. Am. Coll. Cardiol. 77, 1408–1411 (2021).
Neuen, B. L. et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehab497 (2021).
This work was supported by the Fight-HF Avenir Investment Program (ANR-15-RHUS-0004), the Fondation de Recherche sur l’Hypertension Artérielle (REIN/NgalPA - 2017/2018) and the ANR NGAL-HT (ANR-19-CE14-0032-02).
G.L.B. is the principal investigator of FIDELIO (Bayer), serves on the steering committee of the FLOW trial (Novo Nordisk) and the CALM-2 trial (Vascular Dynamics), and is a consultant for Merck, Relypsa, Alnylam and KBP Biosciences. F.J. received research grants from AstraZeneca and Bayer SAS and honoraria from AstraZeneca, Bayer SAS and KBP Biosciences. The other authors declare no competing interests.
Peer review information
Nature Reviews Nephrology thanks J. Bauersachs, E. Lerma and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Kidney Interactive Transcriptomics: http://humphreyslab.com/SingleCell/
About this article
Cite this article
Barrera-Chimal, J., Lima-Posada, I., Bakris, G.L. et al. Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects. Nat Rev Nephrol 18, 56–70 (2022). https://doi.org/10.1038/s41581-021-00490-8